AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17028126
Drug: Omeprazole and
RxNorm normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole and amoxicillin (2 weeks)
Trial: 8348786
Drug: I2-NaF solution;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I2-NaF solution; administered six times to mothers' dentition.
Trial: 8348786
Drug: Placebo solution;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution; administered six times to mothers' dentition.
Trial: 7637157
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (0.15 mg)
Trial: 25594352
Drug: rhuFVIIa infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhuFVIIa infusion
Trial: 23615461
Drug: R‐CHOP‐14 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐CHOP‐14 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 2 mg, rituximab 375 mg/m² on day 1, oral prednisolone 100 mg on days 1‐5, administered every 14 days for six cycles, followed by two further infusions of rituximab 375 mg/m² on day 1 every 14 days)
Trial: 23615461
Drug: R‐CHOP‐21 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐CHOP‐21 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², rituximab 375 mg/m² on day 1, oral prednisolone 40 mg/m² on days 1‐5, administered every 21 days for a total of eight cycles)
Trial: 20309699
Drug: Modern drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern drug therapy
Trial: 20309699
Drug: Controlled drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled drugs trials
Trial: 27197293
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise (150 min/wk; n = 44)
Trial: 27197293
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise (300 min/wk; n = 48)
Trial: 20117915
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered on the first surgical visit, followed by placebo on the second visit after 3 weeks.
Trial: 20117915
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered on the first surgical visit, followed by antibiotics on the second visit after 3 weeks.
Trial: 6088439
Drug: Purified concentrated
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified concentrated bran product (FiberformR, 3.5 g) three times daily for 6 weeks
Trial: 28612324
Drug: PowerPoint presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PowerPoint presentation (weekly for 4 weeks)
Trial: 26852040
Drug: Levofloxacin inhalation
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin inhalation solution (APT-1026) 240mg BID for 28 days
Trial: 20669632
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs and targeted therapies for high-risk groups
Trial: 20669632
Drug: De-escalated treatment
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalated treatment for better-defined low-risk groups
Trial: 20669632
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care (transfusions, antibiotics, pain control)
Trial: 18534221
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg per day of PEG3350
Trial: 18534221
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg per day of PEG3350
Trial: 18534221
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg per day of PEG3350
Trial: 11882400
Drug: Early jejunal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early jejunal feeding combined with prophylactic imipenem (Tienam, 500 mg intravenously twice each day)
Trial: 11882400
Drug: Conventional parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%; 30 kcal/kg)
Trial: 9932944
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug group (low-molecular weight heparinoid)
Trial: 7503622
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 mg/day
Trial: 6833654
Drug: Diltiazem 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 270 mg/day
Trial: 7503622
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 to 360 mg/day
Trial: 7503622
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Verapamil 480 mg/day
Trial: 2157737
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (0.25 x 10(4) PFU)
Trial: 2157737
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (0.5 x 10(4) PFU)
Trial: 2157737
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (10(4) PFU)
Trial: 2157737
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (all doses)
Trial: 2157737
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (medium and high doses)
Trial: 23331949
Drug: ART48 (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART48 (48 weeks antiretroviral therapy)
Trial: 23331949
Drug: ART12 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART12 (12 weeks antiretroviral therapy)
Trial: 21216164
Drug: Eprinomectin (EPM)
RxNorm normalized name: Eprinomectin
DrugBank: Eprinomectin (DB11405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprinomectin (EPM) pour-on preparation at a dose of 0.5 mg/kg bodyweight
Trial: 11923161
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days
Trial: 9799030
Drug: HRT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT group (N = 14), treated with 1 mg 17beta‐estradiol once daily and 5 or 10 mg dydrogesterone once daily during the third and fourth week of every 4 weeks
Trial: 9799030
Drug: C-group (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-group (N = 15), which did not receive therapy
Trial: 30075748
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily
Trial: 2391738
Drug: Ciprofloxacin 1000
RxNorm normalized name: ciprofloxacin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1000 mg twice daily
Trial: 26264702
Drug: Evacetrapib 100
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 100 mg
Trial: 26264702
Drug: Evacetrapib 300
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 300 mg
Trial: 21679043
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac 3.75 mg
Trial: 21679043
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac 75 mg
Trial: 19628193
Drug: Overall patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall patients (statin treatments)
Trial: 16641127
Drug: Echinacea treatment
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea treatment for rhinovirus infection
Trial: 9423108
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg/kg)
Trial: 14625336
Drug: 8 days
RxNorm normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 days of antibiotic therapy
Trial: 14625336
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of antibiotic therapy
Trial: 28235529
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine plus 2 μg/kg dexmedetomidine, 1 mL/kg
Trial: 28235529
Drug: 0.125% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine, 1 mL/kg
Trial: 24203450
Drug: ZST (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZST (1.0 mg)
Trial: 24203450
Drug: ZST (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZST (1.75 mg)
Trial: 24203450
Drug: ZST (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZST (3.5 mg)
Trial: 20494961
Drug: Fulvestrant approved
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant approved dose (AD)
Trial: 20494961
Drug: Fulvestrant loading
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant loading dose (LD)
Trial: 20494961
Drug: Fulvestrant high
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant high dose (HD)
Trial: 1258750
Drug: Intramuscular lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular lidocaine (4.5 mg/kg)
Trial: 28718248
Drug: 2% diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% diltiazem cream
Trial: 28718248
Drug: 0.2% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% glyceryl trinitrate cream
Trial: 21606974
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg A3309
Trial: 21606974
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg A3309
Trial: 21876564
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg A3309
Trial: 22878195
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of Pueraria flower extract (PFE)
Trial: 22878195
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Pueraria flower extract (PFE)
Trial: 12654763
Drug: telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telithromycin 800 mg once daily
Trial: 9793807
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (25 micrograms) with prior i.v. fluid (500 ml of lactated Ringer's solution)
Trial: 9793807
Drug: Fluid infusion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid infusion (500 ml of lactated Ringer's solution)
Trial: 7648764
Drug: E3810 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3810 (20 mg once daily for 7 days)
Trial: 7648764
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg once daily for 7 days)
Trial: 2771866
Drug: Disopyramide single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide single bolus injection (150 mg) over 5 min
Trial: 2771866
Drug: Disopyramide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide infusion (28.2 mg/h to steady state)
Trial: 2771866
Drug: Disopyramide single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide single bolus injection (150 mg)
Trial: 12078386
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3 g vitamin C
Trial: 12078386
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml 0.9% saline solution (placebo)
Trial: 28877944
Drug: External inspections
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External inspections of sepsis detection and treatment
Trial: 27212612
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis before skin incision (A)
Trial: 27212612
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis after umbilical cord clamping (C)
Trial: 16375216
Drug: Mouth dissolving
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth dissolving tablets (Nimulid-MD)
Trial: 16375216
Drug: Nimulid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimulid suspension
Trial: 16375216
Drug: Mouth dissolving
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth dissolving tablets
Trial: 10206567
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment (home-study manual)
Trial: 2930443
Drug: Structured research-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured research-based marital therapy
Trial: 2930443
Drug: Clinically flexible
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically flexible marital therapy
Trial: 21742301
Drug: Intralesional methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional methotrexate infiltration (single dose)
Trial: 19738565
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic therapy (TcMT), 10 sessions, bitemporal method, modulation frequency 1-10 Hz
Trial: 16320011
Drug: Catheter‐mediated femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter‐mediated femoral nerve block with 1% prilocaine (40 ml) and post‐operatively 0.2% ropivacaine (30 ml) 6 hourly
Trial: 16320011
Drug: Intravenous metamizol
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metamizol (1 g) and oral tilidine (100 mg) + naloxone (8 mg), with reduced doses for patients aged 90 years or more
Trial: 14571608
Drug: Composite Rhodiolae
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Rhodiolae (CR) administered 4 g daily for 7-10 days before and 5-7 days after the operation
Trial: 8985019
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg i.v. weekly with forced hydration during radiotherapy (CM group)
Trial: 1478406
Drug: Mesalazine controlled-release
RxNorm normalized name: mesalamine Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine controlled-release suppository 1 g once daily
Trial: 6141898
Drug: SKF 93479
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 93479 (20, 40, 60, and 80 mg)
Trial: 6141898
Drug: SKF 93479
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 93479 (80 mg)
Trial: 27273941
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with docetaxel and cisplatin and three‐dimensional conformal radiotherapy
Trial: 18072836
Drug: Gain-framed messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gain-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Trial: 18072836
Drug: Loss-framed messages
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Trial: 15449047
Drug: 131I administration
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I administration (3.7 GBq)
Trial: 15449047
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro irradiation at doses of 0.5, 1 and 2 Gy
Trial: 12403316
Drug: ICP10deltaPK vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP10deltaPK vaccine
Trial: 10235427
Drug: Napsagatran 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napsagatran 5 mg/h and 9 mg/h
Trial: 1887351
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg gentamicin
Trial: 1887351
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg gentamicin
Trial: 1887351
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg gentamicin
Trial: 6651314
Drug: Oral methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methoxsalen and total body irradiation
Trial: 6651314
Drug: Topical applications
RxNorm normalized name: honey based topical applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical applications of methoxsalen or oral methoxsalen combined with local irradiation of the scalp
Trial: 6651314
Drug: PUVA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA treatment (psoralens and UV‐A)
Trial: 23020819
Drug: Probiotic-containing powder
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-containing powder (daily dose of minimum 1 billion colony-forming units of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12®), n=114
Trial: 15311008
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (400 mg calcium twice daily)
Trial: 15311008
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (20 mEq twice daily)
Trial: 15311008
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate and potassium citrate (at same doses)
Trial: 29743101
Drug: Perioperative, algorithm-driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative, algorithm-driven hemodynamic therapy based on individualized fluid status and cardiac output optimization using pulse-pressure variation (PPV) and pulse-contour analysis (ProAQT© device).
Trial: 29743101
Drug: Standard local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard local care based on established basic hemodynamic treatment.
Trial: 29743101
Drug: Perioperative, algorithm-driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative, algorithm-driven hemodynamic therapy.
Trial: 24712855
Drug: Parent-focused treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-focused treatment
Trial: 24712855
Drug: Conjoint family‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint family‐based treatment
Trial: 22993169
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance (OA) therapy
Trial: 19086875
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine succinate (DVS) at doses ranging from 50 to 400 mg/day
Trial: 8358407
Drug: Individualized oral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized oral hygiene instruction and dental supplies (dental mirror and red disclosing tablets)
Trial: 8358407
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral hygiene instruction or supplies (Control)
Trial: 2439823
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg bopindolol
Trial: 26754303
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg paroxetine controlled-release tablet
Trial: 26754303
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg paroxetine controlled-release tablet
Trial: 26754303
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg paroxetine controlled-release tablet
Trial: 22897903
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity program set at home using pedometers
Trial: 18596310
Drug: Glutamine dipeptide-supplemented
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine dipeptide-supplemented parenteral nutrition (GLN-PN)
Trial: 9096188
Drug: Teicoplanin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (6 mg/kg every 12 h for three doses then daily)